Last
Update:
September 09, 2007
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
-
Indinavir/ritonavir 800/100mg bid and efavirenz 600mg qd in patients with
combination nucleoside failure:
96 week outcomes of HIV-NAT 009
MA Boyd, U Siangphoe, C J Duncombe, et al
Abstract
-
Lipodystrophy in patients switched to indinavir/ritonavir 800/100mg bid
and efavirenz 600mg qd after
failing nucleoside combination therapy: 96 week lipodystrophy outcomes in
HIV-NAT 009
MA Boyd, D Bien, K Ruxrungtham, N Chomchey, et al
Abstract
-
Efficacy and safety of Indinavir/Ritonavir 400/100 mg BID in
antiretroviral therapy-naïve Thai AIDS
patients: a 48-week result
P Mootsikapun, P Chetchotisakd, S Anunnatsiri, et al
Abstract
-
Reversal of mitochondrial DNA and RNA depletion in patients switched to
indinavir/ritonavir 800/100mg
bid and efavirenz 600mg qd after failing NRTI combination therapy: a
prospective, 48 week substudy
of HIV-NAT 009
MA Boyd, D Bien, K Ruxrungtham, et al
Abstract
-
Increasing cutaneous adverse effects induced by Indinavir-based therapy in
Thai HIV-1 infected patients
A Avihingsanon, U Siangphoe, M Boyd, et al
Abstract
-
Role of the determination of plasma levels of indinavir to predict the
virologic failure
V Martin, L Ortega, M J Cuevas, et al
Abstract
-
Pharmacokinetically guided indinavir dose reductions can improve renal
function in patients with
chronic nephrotoxicity without jeopardizing virological control: The
HIV-NAT DOWN DOSE study
MA Boyd, U Siangphoe, K Ruxrungtham, et al
Abstract
-
Is combination: indinavir (400 mg bid) plus boosting dose of ritonavir
(100 mg bid) safe enough?
G Dragovic, D J Jevtovic
Abstract
-
Pharmacokinetics of standard and lower dose indinavir administered with
ritonavir 100mg in Asian
HIV-infected patients
L Lee, A Panchalingam, MC Yap, et al
Abstract
-
Pharmacokinetics of indinavir in Koreans compared with Caucasians
JY Choi, KH Chang, YS Park, et al
Abstract
-
Milk thistle and indinavir: a randomized controlled pharmacokinetics study
EJ Mills, K Wilson, M J Clarke, et al
Abstract
-
Isolation and characterization of CnAP1, an aspartyl protease of
Cryptococcus neoformans, and
effects of Indinavir on C. neoformans cultures
C Mussini, M Pinti, B Colombari, et al
Abstract
-
A pharmacokinetic study comparing 600/100 IDV/RTV vs. 400/100 IDV/RTV as
part of highly a
ctive antiretroviral therapy in HIV-infected Thai patients
TR Cressey, P Leenasirimakul, P Sukrakanchana,
et al
Abstract
-
Role of the determination of plasma levels of indinavir to predict the
virologic failure
V Martin, L Ortega, M Cuevas, et al
Abstract
-
Pharmacokinetic Parameters of Indinavir 667 mg with Ritonavir 100 mg q12h:
a comparison with
Indinavir 800 mg q8h in HIV-infected patients
F Rhame, S
Rawlins, R Petruschke, et al
Abstract
|
-
Sustained Antiretroviral Activity of Indinavir Nanosuspensions in Primary
Monocyte-derived
Macrophages
J Limoges, I Kadiu, D Morin, M Chaubal
Abstract
-
POSTER
Sex and
Weight as Covariates in the Pharmacokinetics of Efavirenz, Indinavir, and
Nelfinavir
J Hitti, S Rosenkranz, S Cohn, et al
PDF Poster
-
POSTER
A
Comparison of the Pharmacokinetics of Ritonavir Boosted Generic (Inhibisam)
versus
Brand
Indinavir
C Zala, CS Alexander, C Ochoa , et al
PDF Poster
-
POSTER
Pharmacokinetics of Reduced-dosed Indinavir/Ritonavir 400/100 mg every 12
hours in HIV-1-
infected
Thai Patients
M Boyd, D Burger, P Mootsikapun, et al
PDF Poster
-
CYP3A5
and MDR1 (P-gp) Polymorphisms in HIV-infected Adults: Associations with
Indinavir
Concentrations and Antiviral Effects
PL Anderson, J
Lamba, E Schuetz, CV Fletcher
Abstract
-
Genotype
Interpretation Algorithm for Predicting Virological Response in
HIV-1-infected Patients Receiving
Ritonavir-boosted Indinavir
C Chappey, CJ Petropoulos, NT Parkin, et
al
Abstract
-
Trends
in C-reactive Protein Levels in a Cohort of HIV-1-infected Persons Durably
Suppressed on an
Indinavir-based Regimen (ACTG 5056)
K Henry, D Kitch, J Currie, et al
Abstract
|
-
LACK OF EFFECT OF
AGE, WEIGHT AND BODY MASS INDEX ON THROUGH AND PEAK
INDINAVIR PLASMA CONCENTRATIONS IN HIV-PATIENTS TREATED WITH
DIFFERENT
INDINAVIR BOOSTED REGIMEN
JM. Poirier, O. Zouai, J.L. Meynard, et al
Abstract-
TOLERABILITY, SAFETY, EFFICACY OF TWO INDINAVIR (IDV)/RITONAVIR (RTV)
REGIMENS
FOR
FIRST PROTEASE INHIBITOR (PI) FAILURE: ACTG PROTOCOL A5055
JG. Gerber, EP. Acosta, H. Wu, et al
Abstract
-
PILOT STUDY: RITONAVIR BOOSTED INDINAVIR TREATMENT AS A SIMPLIFIED
MAINTENANCE
MONO"-THERAPY FOR HIV INFECTION"
M. Hupfer, T. Wagels, C. Kahlert, et al
Abstract
-
PRESENCE OF GB VIRUS C AND RESPONSE TO HAART, ANALYSED WITHIN THE
MAXCMIN1
TRIAL COMPARING THE EFFICACY AND SAFETY OF INDINAVIR/ RITONAVIR
VERSUS SAQUINAVIR/RITONAVIR
H Tillmann, T Kaiser, Z .Fox, et al
Abstract
-
EFFICACY AND SAFETY OF INDINAVIR/RITONAVIR 400/100 MG BID IN NAIVE HIV-1
INFECTED
PATIENTS WITH CD43: 24-WEEK RESULT
P.Mootsikapun, P Chetchotisakd, S Anannutsiri, P Bunyapravej
Abstract
-
POPULATION PHARMACOKINETICS OF INDINAVIR AND NELFINAVIR/M8 IN HIV-PATIENTS
TREATED WITH A STABLE ANTIRETROVIRAL THERAPY
K. Brendel, X. Panhard, M. Legrand,
et al
Abstract
-
EARLY VIROLOGICAL RESPONSE IS CORRELATED WITH INDINAVIR PLASMA LEVEL IN
HIGHLY
ADHERENT HIV INFECTED PATIENTS STARTED ON A PROTEASE INHIBITOR (PI)
CONTAINING HAART: APROCO COHORT
X. Duval, F. Mentré, B. Spire, et al
Abstract
-
LACK OF
EFFECT OF AGE, WEIGHT AND BODY MASS INDEX ON
THROUGH AND PEAK
INDINAVIR PLASMA CONCENTRATIONS IN HIV-PATIENTS TREATED
WITH
DIFFERENT
INDINAVIR BOOSTED REGIMEN
JM. Poirier, O. Zouai, JL. Meynard, K. Lacombe, et al
Abstract
-
INDINAVIR-RITONAVIR REGIMEN (400 MG/100 MG BID) IN HIV/HCV COINFECTED
PATIENTS
IN
THE
HEPADOSE STUDY: RELATIONSHIP BETWEEN PROTEASE INHIBITORS PLASMA
CONCENTRATIONS AND LIVER LESIONS
S. Dominguez, Y. Benhamou, G. Peytavin, et al
Abstract
-
COMPARISON OF PI-BOOSTED INDINAVIR WITH EFAVIRENZ PLUS STAVUDINE REGIMENS
IN
EASIER (EUROPEAN AND SOUTH AMERICAN STUDY OF INDINAVIR, EFAVIRENZ,
AND
RITONAVIR)
M. Stek Jr, B. Hirschel, J. Benetucci, et al
Abstract
-
INDINAVIR/RITONAVIR 800/100MG BID AND EFAVIRENZ 600MG QD PROVIDES DURABLE
SALVAGE
FOR
PATIENTS WITH COMBINATION NUCLEOSIDE ANALOGUE FAILURE:
HIV-NAT 009 72 WEEK FOLLOW-UP
M. Boyd, C. Duncombe,U. Siangphoe, et al
Abstract
-
EFFICACY AND SAFETY RELATED TO INDINAVIR AND NEVIRAPINE PLASMA
CONCENTRATIONS IN A RANDOMISED CONTROLLED TRIAL COMPARING INDINAVIR AND
NEVIRAPINE VERSUS INDINAVIR CONTAINING REGIMEN IN HIV-1 INFECTED
PATIENTS
(TRIANON-ANRS081 STUDY)
G. Peytavin,
P. Flandre, L. Morand-Jouber, et al
Abstract
-
POPULATION PHARMACOKINETICS OF INDINAVIR AND NELFINAVIR/M8 IN HIV-PATIENTS
TREATED WITH A STABLE ANTIRETROVIRAL THERAPY
F. Mentré,
K. Brendel, X. Panhard, et al
Abstract
-
LIPID PROFILE ALTERATIONS INDUCED BY THREE DIFFERENT PI-CONTAINING
REGIMENS
(NELFINAVIR, LOPINAVIR/RITONAVIR AND INDINAVIR/RITONAVIR) IN A COHORT OF
HIV-INFECTED PATIENTS
V. Joly,
J. Gerbe, F. Driss, et al
Abstract
-
EFFICACY AND SAFETY OF RITONAVIR/INDINAVIR 100/400 MG BID IN COMBINATION
WITH
TWO NUCLEOSIDE ANALOGUES IN ANTIRETROVIRAL TREATMENT NAIVE HIV-INFECTED
INDIVIDUALS
C. Katlama,
M. Astriti, AG. Marcelin, et al
Abstract
|
|
-
Safety and efficacy evaluation of a phase IV randomised, open-label,
multicentre trial of indinavir/ritonavir
(800/100 mg bid) vs. saquinavir/ritonavir (1000/100 mg bid) in adult HIV-1
infection: The MaxCmin1 trial
P Cahn, U B Dragsted, C Pedersen, et
al
Abstract
-
A
multicenter, open-label, 24-week study with a 24-week extension to
evaluate the efficacy and safety
of
indinavir sulfate (IDV/CRIXIVAN) 800 mg and ritonavir (RTV) 200 mg b.i.d.
Plus 2 NRTIs b.i.d. in HIV-1
infected individuals failing initial PI therapy – Full 48-WK Analysis
(MERCK PROTOCOL 107)
D Paar, H Katner, J Nadler, et al
Abstract
-
Phenotypic resistance and virologic responses to indinavir (IDV) 800
mg-ritonavir (RTV) 200 mg bid-
based salvage regimens in patients with prior protease inhibitor (PI)
failures
RE Campo, J Szumiloski, P N Lichtenberger, et al
Abstract
-
Pharmacokinetic (PK) comparison of two indinavir (IDV)/ritonavir (RTV)
regimens in salvage therapy
J Gerber, EP Acosta, H Wu, et al
Abstract
-
Indinavir and nelfinavir pharmacokinetics in patients with sustained
virological response on HAART,
the
cophar I - ANRS 102 study
C Goujard, M Legrand, F Mentre, et al
Abstract
-
Incidence of nephrolithiasis in HIV infected patients associated with
indinavir treatment
DJG Dragovic, JDJ Jevtovic, et al
Abstract
-
Indinavir/ritonavir 800/100mg twice daily (BID) should be taken with food
to prevent toxic indinavir peak
plasma levels
R Aarnoutse, J Wasmuth, G Fätkenheuer, et al
Abstract
-
Intracellular and plasma pharmacokinetics of
indinavir +/- ritonavir, nelfinavir and its active metabolite
M8
in HIV-infected patients enrolled in Cophar-Cell study
C Lamotte, X Duval, F Mentré, et al
Abstract
-
Indinavir 400 mg BID, an adequate PI dose in combination with Ritonavir
100 mg BID – Results of
therapeutic drug monitoring
A Nilsson, E Sandström, G Bratt, L Ståhle
Abstract
-
Efficacy and safety of indinavir/ritonavir combination in the era of
pharmacological monitoring
JB Guiard-Schmid, AH Gbadoe, J Poirier, et al
Abstract
-
Efficacy and safety of Indinavir (IDV) 800 mg bid versus 400 mg bid
combined with ritonavir (RTV) 100 mg
bid in naïve patients
D Konopnicki, S De Wit, JP Protto
Abstract
-
Genetic correlates of virological response to an Indinavir
(IDV/CRIXIVAN)-Ritonavir (RTV) regimen in
Protease Inhibitor (PI) experienced patients with early virological
failure: Protocol 107
J Nadler, H Katner, H Wilson, et al
Abstract
-
In
vitro downregulation of anti-myelin proteolytic activity by indinavir
F Mengoni, C D'Agostino, I Sauzullo, et al
Abstract
-
Resistance testing in HIV-1 infected patients treated with
indinavir/ritonavir 800mg/100mg BID after at
least one protease inhibitor-based therapy failure
R Boulmé, S De Wit, C Necsoi, et al
Abstract
-
Prospective follow-up of renal function in HIV-infected patients
randomized to combination antiretroviral
therapy including indinavir or nevirapine
P Domingo, MA Sambeat, JA Arroyo, et al
Abstract
-
An
open label, randomized, comparative trial on the effects of indinavir and
nevirapine
on the lipid profile
of
HIV-infected patients on combination antiretroviral therapy
P Domingo, MA Sambeat, JA Arroyo,. et al
Abstract
-
Effect of combination antiretroviral therapy based on indinavir or
nevirapine on peripheral blood
lymphocyte apoptosis
P Domingo, M Sambeat, JA Arroyo, et al
Abstract
-
European and south american study of Indinavir, Efavirenz, and Ritonavir
(EASIER)
M Stek Jr., B Hirschel, J Benetucci, et al
Abstract
|
|
|
Archived
Indinavir Conference Citations |
|
XV
International AIDS Conference
11th
CROI
2nd
IAS Conference
Indinavir
Conference Citations Main Page